Cross-category comparison
Lifestyle Alone vs Mounjaro
Different categories, normalised only where comparison is meaningful.
Structured lifestyle programme
Moderate on average, highly variable
Mounjaro
Up to ~20%+ mean loss in obesity trials; direct head-to-head 20.2% at 72 weeks vs 13.7% semaglutide 1.7/2.4 mg in SURMOUNT-5
How to use this comparison
Compare the factual differences below. We do not assign numerical treatment rankings: outcomes depend on the specific treatment, population, follow-up and your clinical circumstances.
Category-specific detail
| Issue | Structured lifestyle programme | Mounjaro |
|---|---|---|
| Appetite support | Does not directly pharmacologically suppress appetite | Not covered in this row |
| Approach | Nutrition + physical activity + behavioural support | Not covered in this row |
| Cost | Can be low | Not covered in this row |
| Evidence anchor | Not covered in this row | Up to ~20%+ mean loss in obesity trials; direct head-to-head 20.2% at 72 weeks vs 13.7% semaglutide 1.7/2.4 mg in SURMOUNT-5 |
| How it works | Not covered in this row | Dual GIP/GLP-1 receptor agonist |
| How taken | Not covered in this row | Weekly injection — Once weekly |
| Main trade-offs | Not covered in this row | Injection; GI side effects can be limiting; Access and NHS rollout are not the same as NICE eligibility; Ongoing treatment cost/maintenance matters if private |
| Maintenance | Skills can be maintained indefinitely; relapse plan still needed | Long-term treatment may be needed; stopping can be followed by regain |
| Medical intensity | Low | Not covered in this row |
| Muscle support | Strength training + adequate protein can actively support lean mass | Not covered in this row |
| NHS context | Not covered in this row | NICE-recommended; NHS access is phased / pathway-dependent |
| Speed | Gradual | Not covered in this row |
| UK licence | Not covered in this row | UK weight management licence |
| Weight-loss potential | Moderate on average, highly variable | Not covered in this row |
A detail omitted from one column is not evidence that it is irrelevant to that treatment. Use the full guides and discuss clinical suitability with your treating team.
Want support putting this into practice?
The Shift Programme is being built to combine evidence-led education, decision support, practical tools, progress tracking and long-term maintenance.
Sources & evidence
Check the underlying guidance directly: